Advisor to the Board

Medical Nutrition Advisor (Board Advisory Role)

Summary

An experienced Medical Nutrition specialist is sought to provide strategic advisory support for an oral metabolic therapy addressing chronic leg-ulcer healing, guiding nutritional claims, clinical-evidence development, NHS market-entry, and consumer OTC strategies.

This mandate initially involves low-commitment advisory work, approximately two days per month. Depending on your situation and interests, the role could evolve into a fractional or full-time Medical Nutrition Director position as the business scales. Alternatively, you'd be instrumental in identifying and onboarding a long-term hire, depending on your preference / availability.

The business

The company is completing a 20-patient UK pilot; within 12 weeks, results are expected to support a £0.25–1 million SEIS/EIS raise, followed by a 200-patient pivotal study and a further £2 million+ round for borderline-medicine approval. Current market offerings from large multinational consumer-health businesses are oral wound-support products that lack clinical evidence, precluding NHS prescription. This company aims to offer the first clinically proven, reimbursable oral solution, supported by robust UK clinical trials and a comprehensive IP strategy.

Trials are conducted by Pioneer Wound Care, the UK's largest provider, ensuring high-quality data meeting regulatory standards. Success is anticipated due to robust third-party in vitro studies demonstrating significant collagen type II increases, with the upcoming trials specifically targeting wound-relevant collagen types I and III.

Three sequential patents are planned over approximately three years:

• Single pathway, single compound (current application)
• Single pathway, multiple compounds
• Multiple pathways, multiple compounds

Key people

• Founder CEO: Experienced entrepreneur in longevity-nutrition ventures, biochemistry background, self-funded early-stage IP and clinical planning.
• Chair: Serial bio-entrepreneur (Founder/CSO) successfully commercialising a marine-collagen healthcare product currently undergoing FDA approval; strong expertise in skin-related clinical trials and entrepreneurial leadership.
• Board Advisor (Clinical Trials): Clinical Trials Lead at Pioneer Wound Care; practising tissue-viability specialist overseeing trial design and execution, ensuring alignment with MHRA and NICE standards.
• Board Advisor (Pharmacy & Population Health): NHS ICB Trust lead, expert in pharmacy strategy and population health management.

Value-add

Your primary contribution will involve minimising execution risk through clinical trial strategy refinement, regulatory claim positioning (borderline medicine and FSMP), NHS market-entry preparation, and consumer OTC strategic direction. Existing strategic scientific advice is available from the Chair (experienced CSO within wound-care / collagen-based treatment), though this is a transitional solution due to other business commitments and a full time CSO will be brought in. They will act in an advisory capacity in the near term.

Candidates may come from either:

• Commercial Nutrition Background: Strategic or commercial roles within leading medical nutrition or consumer-health businesses (e.g. Abbott Nutrition, Danone Nutricia, Nestlé Health Science), experienced in product launches, evidence-based claims, and regulatory navigation.
• Clinical/Pharmacy Leadership Background: Senior roles in nutritional medicine or applied pharmacy, experienced in clinical trials, regulatory frameworks, and strategic clinical development.

Essential qualifications:

• Degree in human medicine, pharmacy, applied biochemistry, biotechnology, or related field.
• Successfully completed management qualification, ideally an MBA.
• Minimum of five years' experience in nutritional medicine, clinical nutrition, or pharmacy.
• Demonstrated expertise in clinical trials and application studies.

Compensation

Compensation is primarily growth-share-based, supplemented by cash following the patent grant, positive pilot-study results, and initial SEIS tranche completion; precise terms to be agreed.

Process

Initial informal call with the founder to explore mutual fit, followed by targeted discussions with the Chair and clinical team prior to formal offer.